Endocrinopathy with congenital hypogonadotropic hypogonadism as a major feature

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
May 2000

Gonal-F: FDA approved

For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

Gonal-F

EMD Serono, Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Gonal-F

(Follitropin alfa, recombinant)Orphan drug

EMD Serono, Inc.

12.1 Mechanism of Action GONAL-f stimulates ovarian follicular growth in women who do not have primary ovarian failure. In order to bring about final ...

Approved May 2000FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Endocrinopathy with congenital hypogonadotropic hypogonadism as a major feature.
Search all trials →
Search clinical trials for Endocrinopathy with congenital hypogonadotropic hypogonadism as a major feature

Recent News & Research

No recent news articles indexed yet for Endocrinopathy with congenital hypogonadotropic hypogonadism as a major feature.
Search PubMed for Endocrinopathy with congenital hypogonadotropic hypogonadism as a major feature

Browse all Endocrinopathy with congenital hypogonadotropic hypogonadism as a major feature news →

Specialist Network

No specialists currently listed for Endocrinopathy with congenital hypogonadotropic hypogonadism as a major feature.

View all Endocrinopathy with congenital hypogonadotropic hypogonadism as a major feature specialists →

Quick Actions